JPH10507199A - 塩基性薬物を経皮的に送達するための透過増強剤としてのトリアセチン - Google Patents
塩基性薬物を経皮的に送達するための透過増強剤としてのトリアセチンInfo
- Publication number
- JPH10507199A JPH10507199A JP8532550A JP53255096A JPH10507199A JP H10507199 A JPH10507199 A JP H10507199A JP 8532550 A JP8532550 A JP 8532550A JP 53255096 A JP53255096 A JP 53255096A JP H10507199 A JPH10507199 A JP H10507199A
- Authority
- JP
- Japan
- Prior art keywords
- matrix patch
- triacetin
- adhesive
- drug
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)生物学的適合性ポリマー層; (b)約8.0以上のpKaを有する経皮的に吸収可能な塩基性薬物の有 効量;及び (c)実質的にトリアセチンから成る透過増強剤の有効量 を含むマトリックスパッチを、選択した施用場所に対して施用する工程を含む、 約8.0以上のpKaを有する塩基性薬物の経皮的送達速度を増強する方法。 2.該塩基性薬物が、オキシブチニン、スコポラミン、フルオキセチン、エピ ネフリン、モルフィン、ヒドロモルホン、アトロピン、コカイン、ブプレノルフ ィン、クロールプロマジン、イミプラミン、デシプラミン、メチルフェニデート 、メタンフェタミン、リドカイン、プロカイン、ピンドロール、ナドロール、カ リソプロドール、及びそれらの酸付加塩から成る群より選択されるメンバーであ る請求項1記載の方法。 3.該透過増強剤の有効量が、トリアセチンを約0.1重量%〜約50重量% 含む請求項2記載の方法。 4.該ポリマー層が、接着剤を含む請求項3記載の方法。 5.該接着剤が、アクリル系樹脂、ビニルアセテート、天然ゴム及び合成ゴム 、エチレンビニルアセテートコポリマー、ポリシロキサン、ポリアクリレート、 ポリウレタン、可塑化された重量ポリエーテルブロックアミドコポリマー、可塑 化されたスチレン・ゴムブロックコポリマー、及びそれらの混合物から成る群よ り選択されるメンバーである請求項4記載の方法。 6.該塩基性薬物が、オキシブチニン及びそれらの酸付加塩から成る群より選 択されるメンバーである請求項5記載の方法。 7.該透過増強剤の有効量が、トリアセチンを約1重量%〜約40重量%含む 請求項6記載の方法。 8.マトリックスパッチが、更に、希釈剤、賦形剤、皮膚軟化薬、可塑剤、皮 膚刺激緩和剤、キャリヤ、及びそれらの混合物から成る群より選択されるメンバ ーを含む請求項7記載の方法。 9.該塩基性薬物が、オキシブチニンである請求項8記載の方法。 10.該接着剤が、アクリル系コポリマーである請求項9記載の方法。 11.該透過増強剤が、トリアセチンを約2重量%〜約20重量%含む請求項 10記載の方法。 12.該マトリックスパッチが皮膚刺激緩和剤を含み、該皮膚刺激緩和剤がグ リセリンである請求項11記載の方法。 13.該ポリマー層を、接着剤に対して積層する請求項3記載の方法。 14.該ポリマー層を、接着剤で被覆する請求項3記載の方法。 15.(a)生物学的適合性ポリマー層; (b)約8.0以上のpKaを有する経皮的に吸収可能な塩基性薬物の 有効量;及び (c)実質的にトリアセチンから成る透過増強剤の有効量 を含む、約8.0以上のpKaを有する塩基性薬物を経皮的に投与するためのマ トリックスパッチ。 16.該塩基性薬物が、オキシブチニン、スコポラミン、フルオキセチン、エ ピネフリン、モルフィン、ヒドロモルホン、アトロピン、コカイン、ブプレノル フィン、クロールプロマジン、イミプラミン、デシプラミン、メチルフェニデー ト、メタンフェタミン、リドカイン、プロカイン、ピンドロール、ナドロール、 カリソプロドール、及びそれらの酸付加塩から成る群より選択されるメンバーで ある請求項15記載のマトリックスパッチ。 17.該透過増強剤の有効量が、トリアセチンを約0.1重量%〜約50重量 %含む請求項16記載のマトリックスパッチ。 18.該ポリマー層が、接着剤を含む請求項17記載のマトリックスパッチ。 19.該接着剤が、アクリル系樹脂、ビニルアセテート、天然ゴム及び合成ゴ ム、エチレンビニルアセテートコポリマー、ポリシロキサン、ポリアクリレート 、ポリウレタン、可塑化された重量ポリエーテルブロックアミドコポリマー、可 塑化されたスチレン・ゴムブロックコポリマー、及びそれらの混合物から成る群 より選択されるメンバーである請求項18記載のマトリックスパッチ。 20.該塩基性薬物が、オキシブチニン及びそれらの酸付加塩から成る群より 選択されるメンバーである請求項19記載のマトリックスパッチ。 21.該透過増強剤の有効量が、トリアセチンを約1重量%〜約40重量%含 む請求項20記載のマトリックスパッチ。 22.マトリックスパッチが、更に、希釈剤、賦形剤、皮膚軟化薬、可塑剤、 皮膚刺激緩和剤、キャリヤ、及びそれらの混合物から成る群より選択されるメン バーを含む請求項21記載のマトリックスパッチ。 23.該塩基性薬物が、オキシブチニンである請求項22記載のマトリックス パッチ。 24.該接着剤が、アクリル系コポリマーである請求項23記載のマトリック スパッチ。 25.該透過増強剤が、トリアセチンを約2重量%〜約20重量%含む請求項 24記載のマトリックスパッチ。 26.該マトリックスパッチが皮膚刺激緩和剤を含み、該皮膚刺激緩和剤がグ リセリンである請求項25記載のマトリックスパッチ。 27.該ポリマー層を、接着剤に対して積層する請求項17記載のマトリック スパッチ。 28.該ポリマー層を、接着剤で被覆する請求項17記載のマトリックスパッ チ。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US429,757 | 1995-04-26 | ||
US08/429,757 | 1995-04-26 | ||
US08/429,757 US5601839A (en) | 1995-04-26 | 1995-04-26 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
PCT/US1996/004845 WO1996033678A1 (en) | 1995-04-26 | 1996-04-08 | Triacetin as a transdermal penetration enhancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000201747A Division JP4511691B2 (ja) | 1995-04-26 | 2000-07-04 | 経皮的投与のためのマトリックスパッチ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10507199A true JPH10507199A (ja) | 1998-07-14 |
JP3228341B2 JP3228341B2 (ja) | 2001-11-12 |
Family
ID=23704623
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53255096A Expired - Lifetime JP3228341B2 (ja) | 1995-04-26 | 1996-04-08 | 塩基性薬物を経皮的に送達するための透過増強剤としてのトリアセチン |
JP2000201747A Expired - Lifetime JP4511691B2 (ja) | 1995-04-26 | 2000-07-04 | 経皮的投与のためのマトリックスパッチ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000201747A Expired - Lifetime JP4511691B2 (ja) | 1995-04-26 | 2000-07-04 | 経皮的投与のためのマトリックスパッチ |
Country Status (19)
Country | Link |
---|---|
US (2) | US5601839A (ja) |
EP (1) | EP0871420B1 (ja) |
JP (2) | JP3228341B2 (ja) |
KR (1) | KR100275593B1 (ja) |
CN (3) | CN1143688C (ja) |
AR (1) | AR001721A1 (ja) |
AT (1) | ATE205694T1 (ja) |
AU (1) | AU696777B2 (ja) |
CA (1) | CA2217888C (ja) |
DE (2) | DE69615399T2 (ja) |
DK (1) | DK0871420T3 (ja) |
ES (1) | ES2163012T3 (ja) |
FR (1) | FR05C0008I2 (ja) |
HK (1) | HK1084320A1 (ja) |
NL (1) | NL300200I1 (ja) |
NZ (1) | NZ306249A (ja) |
PT (1) | PT871420E (ja) |
WO (1) | WO1996033678A1 (ja) |
ZA (1) | ZA963229B (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000064434A1 (fr) * | 1999-04-26 | 2000-11-02 | Lead Chemical Co., Ltd. | Preparations percutanees contenant de l'oxybutynine |
JP2003531157A (ja) * | 2000-04-26 | 2003-10-21 | ワトソン ファーマシューティカルズ, インコーポレイテッド | オキシブチニン治療に関連した有害な経験の最小化 |
WO2008081940A1 (ja) * | 2006-12-28 | 2008-07-10 | Kaken Pharmaceutical Co., Ltd. | 真菌症治療用ゲル組成物 |
WO2009075324A1 (ja) * | 2007-12-12 | 2009-06-18 | Teikoku Seiyaku Co., Ltd. | ロキソプロフェン含有水性貼付剤 |
WO2011074567A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
JP2019034905A (ja) * | 2017-08-17 | 2019-03-07 | コスメディ製薬株式会社 | デヒドロ酢酸含有経皮吸収製剤 |
WO2022172915A1 (ja) | 2021-02-10 | 2022-08-18 | コスメディ製薬株式会社 | 酸化防止剤含有経皮吸収製剤 |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5633000A (en) * | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
WO1998002169A2 (en) * | 1996-07-15 | 1998-01-22 | Alza Corporation | Novel formulations for the administration of fluoxetine |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US5952000A (en) * | 1996-10-30 | 1999-09-14 | Theratech, Inc. | Fatty acid esters of lactic acid salts as permeation enhancers |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
DE19706824C1 (de) * | 1997-02-21 | 1998-03-26 | Lohmann Therapie Syst Lts | Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
ES2318233T3 (es) * | 1997-11-10 | 2009-05-01 | Strakan International Limited | Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona. |
TW492882B (en) * | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US20020102291A1 (en) * | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
EP1459741A1 (en) * | 1997-12-15 | 2004-09-22 | Noven Pharmaceuticals, Inc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate |
US6727401B1 (en) * | 1998-02-12 | 2004-04-27 | Watson Pharmaceuticals, Inc. | Pressure sensitive adhesive matrix patch for the treatment of onychomycosis |
DE19812413C1 (de) | 1998-03-20 | 1999-06-10 | Sanol Arznei Schwarz Gmbh | Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
US6475514B1 (en) | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
KR100383252B1 (ko) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
AU6403600A (en) * | 1999-06-10 | 2001-01-02 | Sepracor, Inc. | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
AU769079B2 (en) | 1999-06-25 | 2004-01-15 | Durham Pharmaceuticals Ltd. | Topical formulations comprising skin penetration agents and the use thereof |
GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
US20010049546A1 (en) * | 2000-02-08 | 2001-12-06 | Israel Dvoretzky | Multi-purpose drug and heat therapy treatment system |
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
ATE355854T1 (de) * | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
EP1390383B1 (en) * | 2001-05-11 | 2012-02-29 | Isis Pharmaceuticals, Inc. | Antisense permeation enhancers |
US6913760B2 (en) * | 2001-08-06 | 2005-07-05 | New England Medical Hospitals, Inc. | Drug delivery composition |
AU2002340120A1 (en) * | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
JP4295467B2 (ja) * | 2002-04-12 | 2009-07-15 | 日東電工株式会社 | 貼付剤およびその製造方法 |
KR100469995B1 (ko) * | 2002-05-20 | 2005-02-05 | 안국약품 주식회사 | 천식치료제를 함유한 매트릭스형 패취 |
JP4323138B2 (ja) * | 2002-06-05 | 2009-09-02 | 日東電工株式会社 | 経皮吸収型製剤およびその製造方法 |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US20040197397A1 (en) * | 2002-08-30 | 2004-10-07 | Watson Pharmaceuticals, Inc. | Drug delivery system for treatment of urinary incontinence |
DE10251256A1 (de) * | 2002-11-04 | 2004-05-13 | Novosis Ag | Transdermales Wirkstoffabgabesystem für Oxybutynin |
DK1426049T3 (da) * | 2002-12-02 | 2005-08-22 | Sanol Arznei Schwarz Gmbh | Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
JP4898431B2 (ja) * | 2003-04-29 | 2012-03-14 | ザ ジェネラル ホスピタル コーポレイション | 複数薬物の持続放出のための方法およびデバイス |
DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
EP1670433B1 (en) | 2003-10-10 | 2011-11-23 | Antares Pharma IPL AG | Transdermal pharmaceutical formulation for minimizing skin residues |
WO2005077364A1 (ja) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
US8173155B2 (en) * | 2004-06-01 | 2012-05-08 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | BIOSYNCHRONE TRANSDERMAL MEDICINES |
US8252320B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
EP1814531B1 (en) | 2004-10-21 | 2010-06-16 | Durect Corporation | Transdermal delivery systems |
US20070053965A1 (en) * | 2005-02-25 | 2007-03-08 | Gruenenthal Gmbh | Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation |
WO2007124250A2 (en) * | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
US8372040B2 (en) | 2005-05-24 | 2013-02-12 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
JP5037831B2 (ja) * | 2006-02-15 | 2012-10-03 | 久光製薬株式会社 | 凝集力向上及び徐放化の外用貼付剤 |
EP1998756A2 (en) * | 2006-02-27 | 2008-12-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for delivery of amino-functional drugs |
US20070293581A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies |
TW200817049A (en) * | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
NZ552816A (en) * | 2007-01-24 | 2009-05-31 | Bomac Research Ltd | Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof |
RU2428186C2 (ru) | 2007-03-02 | 2011-09-10 | Теика Фармасьютикал Ко., Лтд. | Лекарственная композиция для чрескожной абсорбции, изделие, сохраняющее лекарственную композицию, и содержащий ее препарат для чрескожной абсорбции |
US20080226698A1 (en) * | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
US10183001B1 (en) * | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
US20100278935A1 (en) * | 2007-07-30 | 2010-11-04 | Stacey William C | Immune System Modulator Formulation |
US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
US8404255B2 (en) * | 2008-07-29 | 2013-03-26 | Matt Gibson | System and method for transdermal drug delivery |
RU2497679C2 (ru) * | 2008-10-02 | 2013-11-10 | Милан Инк. | Способ получения многослойного клеящегося ламинированного материала |
JP5155128B2 (ja) * | 2008-12-11 | 2013-02-27 | 日東電工株式会社 | メチルフェニデート貼付製剤 |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
BR112012011334A2 (pt) * | 2009-10-21 | 2020-08-25 | Teikoku Seiyaku Co., Ltd. | formulação transdermicamente absorvível contendo donepezil |
CA2796575C (en) | 2010-04-13 | 2018-05-15 | Relmada Therapeutics, Inc. | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
CA2796877A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
FR2972923B1 (fr) * | 2011-03-25 | 2013-08-23 | Urgo Lab | Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices |
US9925264B2 (en) | 2011-05-10 | 2018-03-27 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
EP2708229B1 (en) | 2011-05-10 | 2019-07-31 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
CA2844367C (en) * | 2011-06-24 | 2016-02-16 | Acenda Pharma, Inc. | Method and improved pharmaceutical composition for improving the absorption of an ester prodrug |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
SI2823815T1 (sl) | 2011-09-27 | 2018-09-28 | Itochu Chemical Frontier Corporation | Ne-vodni obliž |
JP5462421B2 (ja) * | 2011-10-26 | 2014-04-02 | 久光製薬株式会社 | オキシブチニン含有経皮吸収製剤 |
US20130266643A1 (en) * | 2012-04-10 | 2013-10-10 | Hpo Life Sciences, Inc. | Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis |
WO2014034929A1 (ja) * | 2012-09-03 | 2014-03-06 | 第一三共株式会社 | ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物 |
AU2013318338B2 (en) | 2012-09-21 | 2017-05-25 | Intensity Therapeutics, Inc | Method of treating cancer |
US9072682B2 (en) | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
CN103919754B (zh) * | 2013-01-15 | 2018-11-06 | 江苏康倍得药业股份有限公司 | 奥昔布宁药物组合物及其应用 |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US20140271792A1 (en) * | 2013-03-14 | 2014-09-18 | Noven Pharmaceuticals, Inc. | Methylphenidate transdermal compositions with rubber-based adhesives |
US20170217976A1 (en) * | 2014-03-21 | 2017-08-03 | Chironwells Gmbh | 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament |
EP3242659A4 (en) | 2015-01-09 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
EP3704123A1 (en) * | 2017-10-30 | 2020-09-09 | Theracaine LLC | Hydrophobic acid addition salts and pharmaceutical formulations thereof |
KR101975677B1 (ko) | 2017-11-20 | 2019-05-07 | 양진석 | 환편기용 보풀 제거장치 |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
KR102320656B1 (ko) | 2018-10-26 | 2021-11-02 | 경상국립대학교 산학협력단 | 아세틴 화합물의 생물학적 제조 방법 |
CN113384558A (zh) * | 2021-02-01 | 2021-09-14 | 深圳普洛美康材料有限公司 | 一种递送大麻活性物质的透皮贴剂 |
KR20230026232A (ko) | 2021-08-17 | 2023-02-24 | 신신제약 주식회사 | 옥시부티닌을 함유하는 경피흡수제제 |
CN113749968A (zh) * | 2021-10-26 | 2021-12-07 | 奥易生物科技(杭州)有限公司 | 一种快速透皮吸收的化妆品及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466926A (en) * | 1892-01-12 | Advertising device | ||
US4336262A (en) * | 1973-02-23 | 1982-06-22 | Fisons Ltd. | Pour-on veterinary anthelmintic |
AU576889B2 (en) * | 1984-07-24 | 1988-09-08 | Key Pharmaceuticals, Inc. | Adhesive transdermal dosage layer |
US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
US4666926A (en) * | 1986-02-27 | 1987-05-19 | Warner-Lambert Company | Transdermal formulations |
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
JPH0676327B2 (ja) * | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイド軟膏製剤 |
US4857313A (en) * | 1987-05-28 | 1989-08-15 | Warner-Lambert Company | Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate |
US4879297A (en) * | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
US4789547A (en) * | 1987-06-17 | 1988-12-06 | Warner-Lambert Company | Transdermal matrix system |
US4814173A (en) * | 1987-09-08 | 1989-03-21 | Warner-Lambert Company | Silicone elastomer transdermal matrix system |
JP2526256B2 (ja) * | 1987-11-17 | 1996-08-21 | 清水建設株式会社 | 構造物の振動抑制装置 |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
DE3943519A1 (de) * | 1989-04-27 | 1991-01-17 | Stief Georg | Arzneimittel zur behandlung erektiler dysfunktionen |
CA2121603A1 (en) * | 1991-11-15 | 1993-05-16 | Hirohisa Okuyama | Antiphlogistic-analgesic plaster |
JP3130350B2 (ja) * | 1991-11-28 | 2001-01-31 | 積水化学工業株式会社 | 経皮吸収製剤 |
TW224048B (ja) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
HU221598B (hu) * | 1992-06-11 | 2002-11-28 | Theratech Inc. | Glicerin alkalmazása bőrön keresztüli hatóanyag-bevitel szabályozására |
JPH08245377A (ja) * | 1995-03-15 | 1996-09-24 | Yamanouchi Pharmaceut Co Ltd | 経皮吸収用製剤 |
JPH09309783A (ja) * | 1996-05-20 | 1997-12-02 | Chisso Corp | 改良された土中崩壊型被覆粒状肥料 |
-
1995
- 1995-04-26 US US08/429,757 patent/US5601839A/en not_active Expired - Lifetime
-
1996
- 1996-04-08 DE DE69615399T patent/DE69615399T2/de not_active Expired - Lifetime
- 1996-04-08 CN CNB961934565A patent/CN1143688C/zh not_active Expired - Lifetime
- 1996-04-08 PT PT96911647T patent/PT871420E/pt unknown
- 1996-04-08 AU AU54467/96A patent/AU696777B2/en not_active Expired
- 1996-04-08 DK DK96911647T patent/DK0871420T3/da active
- 1996-04-08 JP JP53255096A patent/JP3228341B2/ja not_active Expired - Lifetime
- 1996-04-08 CN CNB2005100719966A patent/CN100374161C/zh not_active Expired - Lifetime
- 1996-04-08 AT AT96911647T patent/ATE205694T1/de active
- 1996-04-08 WO PCT/US1996/004845 patent/WO1996033678A1/en active IP Right Grant
- 1996-04-08 CN CNA2004100392112A patent/CN1507918A/zh active Pending
- 1996-04-08 KR KR1019970707309A patent/KR100275593B1/ko not_active IP Right Cessation
- 1996-04-08 DE DE200512000013 patent/DE122005000013I1/de active Pending
- 1996-04-08 CA CA002217888A patent/CA2217888C/en not_active Expired - Lifetime
- 1996-04-08 NZ NZ306249A patent/NZ306249A/xx not_active IP Right Cessation
- 1996-04-08 EP EP96911647A patent/EP0871420B1/en not_active Expired - Lifetime
- 1996-04-08 ES ES96911647T patent/ES2163012T3/es not_active Expired - Lifetime
- 1996-04-23 ZA ZA963229A patent/ZA963229B/xx unknown
- 1996-04-26 AR AR33630496A patent/AR001721A1/es active IP Right Grant
-
1997
- 1997-01-03 US US08/775,367 patent/US5834010A/en not_active Expired - Lifetime
-
2000
- 2000-07-04 JP JP2000201747A patent/JP4511691B2/ja not_active Expired - Lifetime
-
2004
- 2004-12-21 NL NL300200C patent/NL300200I1/nl unknown
-
2005
- 2005-03-17 FR FR05C0008C patent/FR05C0008I2/fr active Active
-
2006
- 2006-03-04 HK HK06102837A patent/HK1084320A1/xx not_active IP Right Cessation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000064434A1 (fr) * | 1999-04-26 | 2000-11-02 | Lead Chemical Co., Ltd. | Preparations percutanees contenant de l'oxybutynine |
JP2003531157A (ja) * | 2000-04-26 | 2003-10-21 | ワトソン ファーマシューティカルズ, インコーポレイテッド | オキシブチニン治療に関連した有害な経験の最小化 |
JP2013082720A (ja) * | 2000-04-26 | 2013-05-09 | Watson Pharmaceuticals Inc | オキシブチニン治療に関連した有害な経験の最小化 |
WO2008081940A1 (ja) * | 2006-12-28 | 2008-07-10 | Kaken Pharmaceutical Co., Ltd. | 真菌症治療用ゲル組成物 |
JP5372523B2 (ja) * | 2006-12-28 | 2013-12-18 | 科研製薬株式会社 | 真菌症治療用ゲル組成物 |
US8889155B2 (en) | 2006-12-28 | 2014-11-18 | Kaken Pharmaceutical Co., Ltd. | Gel composition for treating mycosis |
WO2009075324A1 (ja) * | 2007-12-12 | 2009-06-18 | Teikoku Seiyaku Co., Ltd. | ロキソプロフェン含有水性貼付剤 |
JP5307727B2 (ja) * | 2007-12-12 | 2013-10-02 | 帝國製薬株式会社 | ロキソプロフェン含有水性貼付剤 |
US10098858B2 (en) | 2007-12-12 | 2018-10-16 | Teikoku Seiyaku Co., Ltd. | Aqueous loxoprofen-containing patches |
WO2011074567A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
JP2019034905A (ja) * | 2017-08-17 | 2019-03-07 | コスメディ製薬株式会社 | デヒドロ酢酸含有経皮吸収製剤 |
WO2022172915A1 (ja) | 2021-02-10 | 2022-08-18 | コスメディ製薬株式会社 | 酸化防止剤含有経皮吸収製剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3228341B2 (ja) | 塩基性薬物を経皮的に送達するための透過増強剤としてのトリアセチン | |
JP2604097B2 (ja) | 皮膚浸透増強剤としてソルビタンエステルを用いた経皮的に薬物を投与するための方法およびシステム | |
US5952000A (en) | Fatty acid esters of lactic acid salts as permeation enhancers | |
JP5016163B2 (ja) | 薬物の経皮透過性を増大させるためのデバイスおよび方法 | |
AU677206B2 (en) | The use of glycerin in moderating transdermal drug delivery | |
JP3566301B2 (ja) | 過飽和経皮薬物輸送システム、およびその製造方法 | |
JP2000517343A (ja) | 医薬の塩を経皮送達するための感圧接着剤マトリックスパッチ | |
AU2007200426A1 (en) | Transdermal delivery of lasofoxifene | |
TW201431572A (zh) | 荷爾蒙及其它醫藥劑之經皮傳遞的組成物及方法 | |
JPH09509154A (ja) | 活性物質モルフィン−6−グルクロニドを含む全身的経皮投与用医薬組成物 | |
MXPA97007868A (es) | La triacetina como incrementador de penetraciontransdermica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080907 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090907 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100907 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110907 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110907 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120907 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120907 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130907 Year of fee payment: 12 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |